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Diabetes is amajor global problem. During the past decade, the genetic basis of variousmonogenic
forms of the disease, and their underlying molecular mechanisms, have been elucidated. Many
genes that increase type 2 diabetes (T2DM) risk have also been identified, but how they do so
remains enigmatic. Nevertheless, defective insulin secretion emerges as the main culprit in both
monogenic and polygenic diabetes, with environmental and lifestyle factors, via obesity,
accounting for the current dramatic increase in T2DM. There also have been significant advances
in therapy, particularly for some monogenic disorders. We review here what ails the b cell and how
its function may be restored.Introduction
On September 14, 2011, the International Diabetes Federation
announced that 336 million people worldwide now have type 2
diabetes, and that the disease is responsible for 4.6 million
deaths each year, or one death every seven seconds. It affects
12% of US adults and >25% of those over the age of 65.
Diabetes is no longer restricted to the Western world, and the
greatest increases in disease incidence in the next few decades
are expected to be in China and India. These figures serve to
emphasize that there is currently a fast-growing diabetes
pandemic. This is a major healthcare problem because diabetes
increases the risk of heart disease, stroke, and microvascular
complications such as blindness, renal failure, and peripheral
neuropathy. Consequently, it places a severe economic burden
on governments and individuals: the cost of diabetes and its
complications amounts to $612 million per day in the US alone.
Diabetes is characterized by high blood glucose levels as
a result of insufficient insulin for the body’s needs. It is a hetero-
geneous disorder with multiple etiologies. Type 1 diabetes
(T1DM) is an autoimmune disease that results in b cell destruc-
tion. It usually presents in childhood, accounts for 5%–10% of
all diabetes, and is associated with the presence of islet-cell
antibodies, and patients require lifelong insulin; it will not be
considered further here. Type 2 diabetes (T2DM), the most
common form of the disease, is influenced by lifestyle factors,
such as age, pregnancy, and obesity, but has a strong genetic
component. Multiple genes are thought to be involved, each
producing a small effect on T2DM risk. An increasing number
of rare monogenic forms of diabetes that result from mutations
in a single gene have also been identified. They amount to
1%–2% of all diabetes in Europe, and almost all are character-1160 Cell 148, March 16, 2012 ª2012 Elsevier Inc.ized by reduced insulin secretion. Accumulating evidence also
implicates impaired insulin release in T2DM.
The last decade has seen an explosion of new information
about themechanism of insulin secretion and the genetic causes
of diabetes, emphasizing the importance of impaired b cell func-
tion in both polygenic and monogenic disease. This Review
focuses on these recent findings.
Insulin Secretion from the Pancreatic b Cell
The physiological regulation of insulin secretion from the pancre-
atic b cells is now fairly well understood. Exocytosis of insulin
granules requires an increase in intracellular calcium that (at least
in the case of glucose-induced insulin secretion) results almost
entirely fromcalcium influx throughplasmalemmal voltage-gated
calcium channels (Figure 1A). Their opening is controlled by the
ATP-sensitive potassium (KATP) channel, which plays a pivotal
role in insulin secretion by linking cell metabolism to the
membrane potential. At low plasma glucose levels, this channel
is open andK+ efflux through the open pore keeps themembrane
hyperpolarized, preventing electrical activity, calcium channel
opening, calcium influx, and insulin secretion. An increase in
plasma glucose leads to increased glucose uptake and metabo-
lismby the b cell and thus to a rise inmetabolically generatedATP
and a concomitant fall in MgADP. These changes in adenine
nucleotide concentrations close KATP channels, thereby initiating
electrical activity, calcium influx, and insulin secretion. Sulphony-
lurea drugs, such as glibenclamide, also stimulate insulin secre-
tion by closing KATP channels, but they do so by binding directly
to the channel, thus bypassing the metabolic steps. These drugs
have been used for almost 60 years to treat T2DM and, more
recently, certain monogenic forms of diabetes.
Figure 1. Stimulus-Secretion Coupling in
Human b Cells
(A) Glucose is taken up via the glucose transporter
Glut1 and phosphorylated by glucokinase (GCK).
Further metabolism, especially in the mitochon-
dria, results in generation of ATP at the expense
of ADP. This leads to KATP-channel closure. Sul-
phonylureas (SU) inhibit the channel by direct
binding, bypassing metabolism. The increased
membrane resistance (Rm[) resulting from KATP-
channel closure allows small background inward
currents, such as those associated with sponta-
neous opening of T type Ca2+ channels to depo-
larize the b cell (JY). This leads to regenerative
activation of voltage-gated L type and P/Q type
Ca2+ channels and Na+ channels, which produces
action potential firing. The associated Ca2+ influx
triggers exocytosis of insulin granules (SG). In-
cretins such as GLP-1 potentiate exocytosis by
both protein kinase A (PKA)-dependent and
Epac2-dependent mechanisms. Plus signs indi-
cate stimulation, and minus signs inhibition, of the
indicated process(es). PM, plasmalemma.
(B) Ca2+-channel clustering and extent of [Ca2+]i
domains before and after long-term FFA expo-
sure. SG, secretory granules.Glucose metabolism also has effects downstream of KATP-
channel closure and calcium influx that result in amplification
of insulin secretion. The details of themechanism are still not fully
understood, but the end result is an increase in the release prob-
ability of the secretory granules. Glucose is almost unique
among nutrients in that it has the capacity to initiate insulin
secretion. Other fuels such as amino acids and fatty acids
enhance glucose-induced insulin secretion but generally have
little stimulatory effect on their own. As a consequence, insulin
secretion is dependent on glucose metabolism.
Hormones and neurotransmitters also modulate insulin secre-
tion, primarily by influencing the release competence of the
insulin granules without elevating intracellular calcium. Current
interest is focused on glucagon-like peptide-1 (GLP-1), which is
released from gut L cells in response to the presence of glucose
andother nutrients in the gut lumen andpotentiates insulin secre-
tion. It stimulates b cell production of intracellular cAMP, whichCell 148acts by PKA-dependent and PKA-inde-
pendent mechanisms to amplify granule
exocytosis, as well as by enhancing
KATP-channel closure, b cell electrical
activity, and calcium release from intra-
cellular stores (reviewed in Leech et al.,
2011). Most of these effects manifest only
at elevated plasma glucose levels, thus
accounting for the glucose dependence
of GLP-1-potentiated insulin secretion.
Release of incretin hormones in the gut,
such as GLP-1 and GIP, explains why an
oral glucose challenge produces a much
larger stimulation of insulin secretion
than an intravenous glucose challenge.
The PKA-independent effects of incre-
tins are mediated by the cAMP-sensingprotein Epac2 (also known as cAMP-GEFII). Recently, Epac2
was also shown to be a target of sulphonylureas (Zhang et al.,
2009); it remains to be determined whether this effect contrib-
utes (together with its effect on the KATP channel) to the stimula-
tion of insulin secretion by these drugs, but there is some
evidence that sulphonylureas enhance exocytosis in b cells (Eli-
asson et al., 2003). Just as activation of PKA or PKC (e.g., in
response to acetylcholine) enhances Ca2+-dependent exocy-
tosis without further elevation of intracellular calcium, other
agents (such as adrenaline and somatostatin) inhibit glucose-
stimulated insulin secretion even when intracellular calcium is
elevated, possibly by activating the protein phosphatase calci-
neurin (Rorsman and Renstro¨m, 2003).
Insulin secretion from isolated islets is biphasic, an initial rapid
transient peak being followed by a slowly developing second
phase of release. In T2DM, first-phase insulin secretion is almost
abolished, and second-phase secretion is strongly reduced, March 16, 2012 ª2012 Elsevier Inc. 1161
(Hosker et al., 1989). It has been proposed that the biphasic
nature of insulin secretion reflects the existence of distinct func-
tional pools within the b cells. A subset of secretory granules
known as the readily releasable pool (by analogy with nerve
terminals), situated close to the Ca2+ channels, accounts for
first-phase secretion. Once this pool has been depleted, exocy-
tosis proceeds at amuch lower rate, possibly reflecting the phys-
ical translocation of new granules (‘‘newcomer granules’’) to the
release sites, producing second-phase release. Like neurotrans-
mitter secretion, insulin granule exocytosis requires the SNARE
proteins synaptobrevin, syntaxin, and SNAP25 (Rorsman and
Renstro¨m, 2003).
The existence of functionally distinct subsets of secretory
granules is supported by FRET-based studies (Takahashi
et al., 2010), which demonstrated that b cell SNARE complexes
exist in different states of ‘‘preassembly.’’ Granules with preas-
sembled SNARE complexes underwent rapid exocytosis upon
stimulation. In addition, a time- and Ca2+-dependent assembly
of SNARE complexes that preceded a slower phase of exocy-
tosis was observed. It is tempting to equate these two sets of
granules with first- and second-phase release and to speculate
that glucose metabolism may enhance the release competence
of the secretory granules by promoting assembly of the SNARE
complex. This might explain the elusive amplifying effect of
glucose on insulin secretion.
Monogenic Diabetes
An increasing number of clinically and genetically distinct forms
of diabetes that result from mutations in single genes have been
described (Table 1). Conventionally, monogenic diabetes that
develops within the first 6 months of life has been referred to
as neonatal diabetes (ND), and that which develops in young
adults as maturity-onset diabetes of the young (MODY). The
latter term is misleading, however, as monogenic diabetes is
quite distinct from maturity-onset diabetes (an old name for
T2DM). The different genes involved also give rise to clinically
distinct types of diabetes that vary in the age of onset, severity
of hyperglycemia, and risk of complications. In this section,
therefore, we refer to the different forms of monogenic diabetes
by their gene names and to MODY as young-onset diabetes
(Murphy et al., 2008).
Considerable advances in our understanding of the genetic
causes of monogenic diabetes have been made in the last
10 years, largely because of the careful clinical and genetic iden-
tification of these subgroups of patients. These have provided
valuable insights into b cell function, as well as the diagnosis
and pathophysiology of the disease. In some instances, this
knowledge has also led to a change in therapy for affected
patients. Consequently, individuals with neonatal or young-
onset diabetes that is not accompanied by islet autoantibodies
should be evaluated genetically. This is important, asmonogenic
diabetes is often misdiagnosed as T1DM (or even T2DM).
For convenience, we consider neonatal diabetes and young-
onset diabetes separately, although it is now clear that mutations
in the same gene may manifest their effects at different ages.
Neonatal Diabetes
ND, usually defined as diabetes diagnosed within the first
6 months of life, was once considered a rare variant of T1DM1162 Cell 148, March 16, 2012 ª2012 Elsevier Inc.that presented unusually early. Within the last decade, however,
it has become clear that ND is a monogenic disorder that is
caused bymutations in genes that play key roles in b cell function
or development, including glucokinase, the KATP channel, and
insulin itself. The incidence of ND is low (around 1 in 200,000
live births). It may be permanent (PNDM) or transient (TNDM)
or follow a remitting-relapsing time course. Rarely, a few individ-
uals may present with diabetes between 6 and 9 months of age
(Rubio-Cabezas et al., 2011). The disease is usually associated
with intrauterine growth retardation and a lower birth weight, in
keeping with the role of insulin as a growth factor. In marked
contrast to T1DM, islet-cell antibodies are absent.
Gain-of-function mutations in the genes encoding the Kir6.2
(KCNJ11) and SUR1 (ABCC8) subunits of the KATP channel are
the most common cause of PNDM, accounting for around
50% of cases (Flanagan et al., 2009; Hattersley and Ashcroft,
2005). All ND mutations impair the ability of metabolism to close
the channel by enhancing either ATP block at Kir6.2 or channel
activation byMg nucleotides (MgADP/MgATP) at SUR1 (McTag-
gart et al., 2010). This leads to an increased KATP current, which
prevents b cell depolarization in response to glucosemetabolism
and consequently impairs insulin secretion. Most mutations in
KCNJ11 occur spontaneously, and patients are heterozygotes.
ABCC8 mutations are genetically more heterogeneous with
dominant, recessive, uniparental disomy and compound hetero-
zygous inheritance being described (Ellard et al., 2007).
In addition to diabetes, around 20% of patients with KATP-
channel mutations have a constellation of neurological symp-
toms (Hattersley and Ashcroft, 2005). A minority (3%) have
‘‘DEND syndrome,’’ which is characterized by severe mental
and motor developmental delay, epilepsy, and neonatal dia-
betes, as well as muscle hypotonia, hyperactivity, and balance
problems. However, most have an intermediate disorder (iDEND
syndrome) that resembles DEND syndrome but without the
epilepsy.
The spectrum of symptoms found in iDEND and DEND reflects
the widespread tissue distribution of KATP channels, which link
cell metabolism to plasmalemmal electrical activity in muscle,
heart, and brain aswell as pancreatic b cells. Mousemodels indi-
cate that the motor problems originate in the central nervous
system rather than muscle, which may be related to the different
SUR isoforms in these tissues (SUR1 in neurons, SUR2A in
muscle) (Clark et al., 2010). There is a good correlation between
genotype and phenotype, with those mutations that have the
greatest functional effect on ATP sensitivity producing a more
severe clinical phenotype (McTaggart et al., 2010).
ND patients were originally treated with insulin as they were
assumed to have an unusually early form of T1DM, but the
discovery in 2004 of the causal role of KATP channels has enabled
90% of patients (>500 to date) to switch to sulphonylurea
therapy. These drugs block their open KATP channels, thereby
stimulating insulin secretion. This results in a significant improve-
ment in diabetes control: fluctuations in glucose homeostasis
are reduced and HbA1C levels fall, which should translate into
a reduced risk of diabetic complications (Pearson et al., 2006;
Zung et al., 2004). In some patients the accompanying neurolog-
ical problems also show some improvement (Mlynarski et al.,
2007; Slingerland et al., 2006).
Table 1. Monogenic Diabetes Genes
Gene Protein Type of Diabetes Comments References
KCNJ11 Kir6.2 DEND, PNDM,
TNDM, MODY
Mainly autosomal dominant.
Reduced b cell function. Most treatable
with SU. DEND patients also have
developmental delay and epilepsy.
Linkage to T2DM.
(Flanagan et al., 2009;
Gloyn et al., 2004;
Hattersley and Ashcroft, 2005)
ABCC8 SUR1 DEND, PNDM,
TNDM
Genetically heterogenous.
Reduced b cell function.
Most treatable with SU.
(Ellard et al., 2007;
Hattersley and Ashcroft, 2005)
INS Insulin PNDM, MODY Increased b cell destruction.
Treated with insulin.
(Støy et al., 2010)
GCK Glucokinase PNDM, MODY2 PNDM, autosomal recessive. MODY,
autosomal dominant.
Reduced b cell function.
(Osbak et al., 2009)
SCLC2A2 GLUT2 PNDM Autosomal dominant.
Reduced b cell function.
(Yoo et al., 2002)
PDX1 Insulin promoter
factor 1
PNDM, MODY4 PNDM, autosomal recessive.cMODY,
autosomal dominant.
Pancreatic agenesis.
(Stoffers et al., 1997)
GLIS3 GLIS3
(transcription factor)
Syndromic Autosomal recessive.
Reduced b cell function plus congenital
hypothyrodism, glaucoma, liver fibrosis,
polycystic kidneys.
(Sene´e et al., 2006)
FOXP3 Forkhead box P3 Syndromic X-linked. Reduced b cell mass
(increased b cell destruction)
plus immune dysregulation,
polyendocrinopathy, enteropathy.
(Bennett et al., 2001)
EIF2AK3 Eukaryotic translation
initiation factor
2-alpha kinase 3
Syndromic Autosomal recessive.
Wolcott-Rallison syndrome.
ND plus skeletal abnormalities
and liver dysfucntion.
(Dele´pine et al., 2000)
PTF1A Pancreas transcription
factor 1A
Syndromic Autosomal recessive.
Pancreatic and cerebellar agenesis.
(Sellick et al., 2004)
Rfx6 Rfx6 transcription
factor
Syndromic Autosomal recessive.
Pancreatic agenesis. Bowel atresia.
(Smith et al., 2010)
6q24 abnormality TNDM Abnormality in a region of
chromosome 6q24, causing
overexpression of ZAC and HYMAI.
(Temple and Shield, 2010)
TCF2 Hepatic nuclear
factor 1b
TNDM, MODY5 Autosomal dominant, diabetes only.
Autosomal recessive,
diabetes plus renal cysts,
kidney, uterine, and genital
developmental disorders.
(Servitja and Ferrer, 2004)
HNF4A Hepatic nuclear
factor 4a
MODY1 Autosomal dominant, diabetes only.
Autosomal recessive, diabetes plus lipid
abnormalities. Linkage to T2DM.
(Servitja and Ferrer, 2004)
TCF1 Hepatic nuclear
factor 1a
MODY3 Autosomal dominant, diabetes only,
treatable with sulphonylureas.
Autosomal recessive, diabetes plus
extrapancreatic effects. Linkage to T2DM.
(Servitja and Ferrer, 2004)
NEUROD1 Neurogenic
differentiation factor 1
MODY6 Autosomal dominant. (Servitja and Ferrer, 2004)There is a good correlation between the efficacy of sulphony-
lureas at blocking KATP-channel activity and the ability of patients
with the same mutation to transfer to oral drug therapy. Those
with the most severe mutations, which cause DEND syndrome,are often unable to transfer because their mutant channels are
not blocked sufficiently by glibenclamide (McTaggart et al.,
2010). The efficacy of sulphonylurea therapy also shows some
interesting differences between patients with ND and thoseCell 148, March 16, 2012 ª2012 Elsevier Inc. 1163
with T2DM. In 50% of patients with T2DM, sulphonylureas
cease to be effective at controlling blood glucose levels within
a few years of beginning therapy. This phenomenon is known
as secondary failure, and its mechanism is unknown. Because
drug therapy has been implemented so recently, it is not clear
whether patients with KCNJ11 or ABCC8mutations will continue
to respond to sulphonylureas in the long term. Nevertheless, this
seems likely as a few patients have been successfully treated
with these drugs for many years, and to date, no desensitization
to glibenclamide has been observed (Iafusco et al., 2011).
The ability of some adult ND patients to transfer to sulpho-
nylurea therapy implies that their b cells are fully functional,
despite many years of suboptimal glucose control. They often
need much higher drug doses, relative to body weight, than
T2DM patients (Pearson et al., 2006), probably because their
KATP channels are more active at ambient glucose levels and
thus require (at least initially) a higher drug dose to close
them to the same extent as a lower dose would in ‘‘normal’’
b cells. Some mutant channels are also less sensitive to sulpho-
nylureas.
Recent studies indicate that heterozygous mutations in the
insulin gene (INS) account for around 20% of cases of PNDM.
Most coding mutations are de novo mutations and are inherited
in a dominant manner (Støy et al., 2007). One of these is identical
to that found in the Akita mouse, where it acts to disrupt insulin
biosynthesis, causing the protein to be degraded so that few
insulin granules are produced, despite one Ins2 and two Ins1
alleles remaining functional (Wang et al., 1999). By analogy, the
humanmutations are predicted to prevent normal protein folding
and induce the unfolded protein response, leading to endo-
plasmic reticulum (ER) stress and b cell death. Recessively
acting mutations, which reduce insulin synthesis, have also
been reported (Garin et al., 2010). Insulin therapy is essential
for patients with INS mutations.
Homozygous loss-of-function mutations in the glucokinase
gene (GCK) can cause PNDM but are extremely rare (Njølstad
et al., 2001). Glucokinase catalyzes the first step in glucose
oxidation—phosphorylation of the sugar—and has been termed
the glucose sensor of pancreatic b cells (Matschinsky, 2009).
The complete absence of insulin secretion in patients lacking
glucokinase reveals that ATP production from glucose is essen-
tial for insulin secretion and cannot be substituted by ATP
produced by protein or fat metabolism. The importance of gluco-
kinase for insulin secretion is illustrated by the finding that the
sulphonylurea glibenclamide reversibly increased both basal
and glucagon-stimulated insulin secretion in a patient with
a homozygous GCK mutation, leading to a reduced insulin
dose and lower HBA1c level (Turkkahraman et al., 2008).
However, insulin therapy could not be stopped, perhaps
because ATP generation was not sufficient to support the ampli-
fying effect of glucose on insulin secretion.
TNDM accounts for 50% of cases of ND. Diabetes presents
within the first few weeks after birth but remits within several
months or years, only to often return in adolescence or early
adult life. The most common cause (70%) is an abnormality in
the imprinted region of chromosome 6q24 that leads to overex-
pression of at least two imprinted genes, ZAC andHYMAI (Flana-
gan et al., 2007; Temple and Shield, 2010). It remains unclear1164 Cell 148, March 16, 2012 ª2012 Elsevier Inc.how this results in diabetes, or why the diabetes is transient,
although a mouse model that overexpressed these two genes
recapitulated the clinical phenotype (Ma et al., 2004). Most other
cases of TNDM are due to activating mutations in KCNJ11 and
ABCC8 and can be treated with sulphonylureas. Considerable
overlap exists with PNDM, with the same mutation sometimes
causing PNDM in some family members and TNDM in others.
Why the disease follows a remitting-relapsing time course is
also an enigma.
Recessivemutations in a number of other genes cause a range
of very rare syndromes that include ND as one component of
a multisystem disorder (Table 1).
Young-Onset Diabetes
Familial young-onset diabetes is typically diagnosed outside the
neonatal period but before 25 years of age. Mutations in the
glucokinase and HNF1A genes account for about 70% of cases.
Heterozygous loss-of-function mutations in the glucokinase
gene (GCK) lead to lifelong, mild, stable fasting hyperglycemia
from birth. However, this is often only detected later in life,
such as during routine screening in pregnancy (Osbak et al.,
2009). GCK mutations act by decreasing glucose-dependent
ATP production, which results in impaired KATP closure and
reduced insulin secretion. Treatment is rarely needed and
85% of patients can be managed by diet alone. Microvascular
complications are also rare, reflecting the fact that glucose
homeostasis is not severely impaired.
Five genes associated with familial young-onset diabetes are
transcription factors that interact in a complex network to regu-
late gene transcription (Table 1). They are needed both for
correct functioning of adult b cells and for b cell development.
The most common mutations are found in the homeobox genes
HNF1A and HNF4A; mutations in HNF1B, IPF1, and NEUROD1
are more rare. Most mutations cause a loss of function and are
inherited in an autosomal-dominant manner. They lead to
a progressive deterioration of b cell function, increasing hyper-
glycemia, and eventual diabetes. Studies of mouse models
suggest that the impaired insulin secretion may be a result of
defective metabolism (Dukes et al., 1998). Whereas heterozy-
gous mutations cause a phenotype that is largely confined to
the b cell, homozygous mutations in these transcription factors
cause a range of additional effects, reflecting the role of these
proteins in extrapancreatic tissues. For example, HNF1A is
associated with a low renal glucose threshold, HNF4A with
altered lipids and lipoproteins, and HNF1B with renal cysts
and uterine and genital developmental disorders. Patients are
at risk of microvascular complications due to poor glucose
control.
Patients with HNF1Amutations are highly sensitive to sulpho-
nylureas and can transfer from insulin to low-dose oral drug
therapy without deterioration of glycemic control (Pearson
et al., 2003). This indicates that despite diabetes of long duration,
they possess sufficient b cell mass, and thus that HNF1A likely
controls b cell function.
It is evident from the above discussion that the age at which
monogenic diabetes presents is variable and depends on the
functional severity of the mutation. Patients with more severe
mutations, or a greater gene dosage (homozygous rather
than heterozygous), tend to develop diabetes earlier in life,
Figure 2. Impaired Glucose-Induced Insulin Secretion Cannot Be
Accounted for by Reduced Insulin Content
(A) Insulin content in islets from nondiabetic (N) and age- and body mass index
(BMI)-matched T2DM organ donors.
(B) Insulin secretion, normalized to islet insulin content, evoked by 1 mM and
20 mM glucose in nondiabetic (N) and T2DM islets. Mean ± standard error of
the mean (SEM).
(C) Stimulation index (insulin secretion at 20 mM glucose divided by that at
1 mM) in nondiabetic (N) and T2DM islets. *p < 0.05 versus 1 mM glucose; yp <
0.05 versus N islets.
Panel A is modified from Walker et al. (2011).whatever the gene involved. In many cases, they may also
exhibit extrapancreatic symptoms. Furthermore, common vari-
ants in the same genes that cause monogenic disease may
predispose to T2DM in later life.
Polygenic Diabetes
Genetics of T2DM
Perhaps one of the most radical changes in the field in the past
decade has been widespread recognition that reduced b cell
function is the key problem in T2DM. Ten years ago, many
leading groups still continued to regard T2DM as largely
a disease of insulin resistance; today, this is not the case. In
part, this paradigm shift has come about because studies of
human islets have shown reduced glucose-dependent insulin
secretion in T2DM even when allowance is made for the reduc-
tion of insulin content (Figure 2). In part, it derives from linkage
studies and genome-wide association studies (GWAS), which
have identified more than 40 genes associated with increased
risk of T2DMover the past 5–6 years. Herewe discuss a selection
of these genes; for amore comprehensive summary, see Bonne-
fond et al. (2010) and McCarthy (2010).
Most gene associations were inferred from single-nucleotide
polymorphisms (SNPs) within noncoding regions of the gene,
and in many cases the annotation is not yet conclusive. Thus it
remains uncertain whether diabetes is linked to the gene within
whose intron the SNP resides or to genes that lie close by or
are coregulated. With few exceptions, the genes identified
were unexpected based on existing knowledge, and precisely
how they predispose to T2DM is not yet understood. However,
many are believed to be important for b cell function, b cell devel-
opment, or the regulation of b cell mass (Bonnefond et al., 2010;
McCarthy, 2010). Others, such as FTO, predispose toward
obesity and thus indirectly to T2DM; when corrected for body
mass index, the association with T2DM vanishes.The most important diabetes susceptibility gene identified to
date is TCF7L2, which increases diabetes risk 1.7-fold. It is
involved in WNT signaling, and functional studies suggest that
it influences insulin secretion, although there is disagreement
about whether its expression is increased (Lyssenko et al.,
2007) or unaltered (Kirkpatrick et al., 2010) in T2DM. However,
downregulation of TCF7L2 in mouse or human islets causes
reduced insulin secretion and exocytosis (Shu et al., 2008).
Several GWAS genes are implicated in cell-cycle regulation
and thus suggested to act by influencing b cell mass during
development. This is not entirely unexpected because a reduced
b cell mass might predispose to T2DM by reducing the capacity
to cope with an increased demand, such as that imposed by age
and/or obesity.
The functional effects of other genes are less clear. The zinc
transporter Znt8 (SLC30A8) is necessary for the uptake of zinc
into the insulin granules and formation of Zn-complexed insulin
crystals (Sladek et al., 2007). Thus one might expect it to have
an effect on insulin storage or release; however, deleting the
gene in mice has only weak and variable effects (Lemaire
et al., 2009). KCNQ1 (Yasuda et al., 2008) encodes a voltage-
sensitive K channel, and a gain-of-function mutation in this
gene might be expected to reduce action potential duration
and thereby calcium influx and insulin secretion. However, it is
uncertain whether KCNQ1 is present in human b cells, and
whether the intronic SNP influences its expression. A common
polymorphism in Kir6.2 (E23K) predisposes to T2DM (Gloyn
et al., 2003). Although the increase in disease risk is small
(odds ratio, 1.2), the population risk is highly significant because
65% of people carry at least one K allele. The E23K polymor-
phism is found in strong linkage disequilibrium with another
variant, S1369A, in the adjacent SUR1 gene, which means either
variant could cause the increased disease risk. Precisely how the
polymorphism increases disease risk remains controversial, as
functional effects on KATP-channel activity are very small and
variable.
What these examples serve to show is that it is not easy to
determine how the various SNPs predispose to T2DM. Given
that genes found in GWAS only cause a small increase in disease
risk and that their effects manifest only later in life or in the face of
obesity, disease-associated SNPs may only have small effects
on b cell function that will be hard to measure in human studies
or even in vitro. As might be expected, disease risk is enhanced
for individuals who carry multiple risk-associated SNPs (McCar-
thy, 2010). Even taking this into consideration, GWAS genes
collectively appear to explain only 5%–10% of T2DM. This has
led to the suggestion that there may be a large number of far
less common mutations, private to each individual, that carry
a greatly enhanced disease risk (Bonnefond et al., 2010). Much
current effort is devoted to identifying these rare variants.
Over the last 5 years, a vast amount of information about the
genetics of T2DM has been obtained. What is lacking is an
understanding of the functional roles of many of these genes
and how they contribute to T2DM. Addressing this problem will
require considerable effort, substantial funding, and amultidisci-
plinary approach—incorporating studies of human islets, gener-
ation and analysis of mouse models (lacking or overexpressing
the gene of interest), molecular and cellular studies, and,Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1165
perhaps most importantly, in vivo studies in humans carrying
these different variants. But before beginning this task, it will
be essential to determine precisely which gene(s) is affected
by any intronic T2DM susceptibility SNP of interest.
What Can Rodent Models Teach Us?
Not all T2DM genes identified in the last decade were found by
GWAS or linkage studies. Some were found by analysis of genes
that cause glucose intolerance or diabetes in rodents. For
example, the discovery that the a2-adrenoreceptor gene contrib-
utes to diabetes in the GK rat led to identification of a common
variant of this gene that decreases insulin secretion in humans
(Rosengren et al., 2010). In fact, deletion of a number of different
genes in mice impairs glucose tolerance. This indicates that
glucose homeostasis is finely balanced and involves many path-
ways, and that perturbation of any of these can cause glucose
intolerance.
As much work on the mechanism of insulin secretion has
involved rodents, particularly genetically modified mice, it is
pertinent to consider the extent to which rodents provide a valid
model of human insulin secretion. In some instances, mouse
models faithfully recapitulate the human phenotype, as in the
case of ND due to KCNJ11 mutations (Clark et al., 2010; Girard
et al., 2009). Nevertheless, it is now evident that human and
mouse b cells are far from identical; e.g., they express different
complements of ion channels and membrane transporters
(Braun et al., 2008; De Vos et al., 1995) and have a different archi-
tecture. Thus although mouse models and studies of mouse
islets are very valuable, it is important to be cautious when
extrapolating from mice to humans.
Is T2DM Associated with Reduced b Cell Mass?
There is an ongoing debate about the extent to which b cell mass
is reduced in T2DM, and its precise role in the etiology of T2DM
remains controversial. Over the last decade, several investiga-
tors have come to favor the hypothesis that a reduced number
of b cells rather than impaired b cell function is a major factor in
the development of T2DM. A decrease in b cell mass of up to
60%has been reported in T2DM (Butler et al., 2003), which paral-
lels the extent of reduction in glucose-induced insulin secretion
(Del Guerra et al., 2005). However, others have found consider-
ably lower decrements (Rahier et al., 2008). Because no longitu-
dinal studies of b cell mass in man exist, it is unclear whether
individuals with T2DM started with a lower b cell mass or if this
developed as a consequence of sustained hyperglycemia.
How much b cell mass is needed to maintain glycemia is also
uncertain. Simple calculations based on the rate of insulin
release each day in a nondiabetic individual suggest that as
few as 40% of b cells would be sufficient for adequate glucose
control. This number is supported by the fact that removal of
half the pancreas has only a small effect on glucose tolerance
(Menge et al., 2008). Collectively, these findings suggest that
although b cell mass plays some role in T2DM, it is not the
only, or even the most important, factor. The finding that insulin
secretion from T2DM islets is reduced even when allowance is
made for a slight reduction of insulin content (Figure 2) implicates
b cell function rather than b cell number in the etiology of T2DM.
Indeed, the rapid reversal of diabetes and the increase in insulin
secretion provoked by GLP-1 demonstrate that even in estab-
lished T2DM, there is sufficient, albeit latent, b cell capacity.1166 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Recent observations suggest that unlike islet cells in young
rodents, adult human b cells are largely senescent, postmitotic,
and long lived (Cnop et al., 2010; Ko¨hler et al., 2011), so aberrant
cellular turnover is unlikely to contribute to T2DM. However,
aging processes (e.g., reduced mitochondrial oxidation) in
long-lived endocrine cells could impair secretory function.
Amyloid formation in pancreatic islets, from islet amyloid poly-
peptide (IAPP), is a hallmark of T2DM, but because the severity
of amyloidosis is low in most patients, it is likely to be a conse-
quence rather than a cause of the disease (Clark and Nilsson,
2004).
Environmental and Lifestyle Factors
Although this Review focuses on the role of the b cell in diabetes,
it is important to briefly consider its role in relation to insulin resis-
tance. The impact of obesity on T2DM risk is truly dramatic, and
the catastrophic increase in T2DM over the past 50 years is
largely due to the concomitant increase in obesity—diabetes
would be reduced to amanageable problem if only obesity could
be controlled.
Obesity is a key risk factor for T2DM as it lowers insulin sensi-
tivity in peripheral tissues. The b cells compensate for this by up-
regulating insulin secretion (Bergman, 2005), and the degree to
which they are able to do so determines whether or not the indi-
vidual develops diabetes. This, in turn, is influenced by their
genetic constitution. This explains why most obese people,
and those with other insulin-resistant states, do not develop
T2DM: their b cells are able to compensate. A dramatic illustra-
tion of the interplay between diabetes, obesity, and genetics is
provided by the report that infusion of triglyceride emulsion led
to a decrease in insulin secretion in people who had first-degree
relatives with T2DM but not in those who did not (Kashyap et al.,
2003). All individuals were nondiabetic in the absence of elevated
plasma triglyceride, emphasizing that it is only in the presence of
elevated fat that genetic differences become obvious.
Lipids have complex effects on b cell function. In the short
term, free fatty acids (FFAs) potentiate glucose-induced insulin
secretion. This contributes to the increased insulin secretion
following a mixed meal and enables storage of excess calories
as fat. It has also been proposed to account for the compensa-
tory upregulation of b cell function in response to insulin resis-
tance (Stefanovski et al., 2011). In the long term, however,
FFAs suppress glucose-induced insulin secretion. The mecha-
nism by which this occurs is still hotly debated. It has been sug-
gested to involve impaired glucose metabolism, reduced insulin
biosynthesis, and b cell loss (Poitout and Robertson, 2008;
Yaney and Corkey, 2003). A further idea has recently been
proposed, based on the lack of any change in Ca2+ currents or
global [Ca2+]i transients in the presence of physiological levels
of FFA during fasting and the observation that Ca2+ channels
become more diffusely distributed in the plasmalemma (Hoppa
et al., 2009). The b cell has a low density of calcium channels
that normally colocalize with the secretory granules, ensuring
that even if calcium channels open only briefly (as during a brief
action potential), Ca2+ entry is sufficient to trigger exocytosis
(Figure 1B). Loss of this colocalization means that although the
calcium channels continue to open, the resulting increase in
[Ca2+]i occurs in the ‘‘wrong’’ place and fails to evoke secretion
(Hoppa et al., 2009).
Obesity and high-fat feeding mimic the effects of long-term
incubation of islets with FFAs on insulin secretion and Ca2+-
channel distribution (Collins et al., 2010). All correlate with an
increased amount of fat within the islets (Hoppa et al., 2009)
and the surrounding exocrine pancreas (Pinnick et al., 2008).
Moreover, in Zucker diabetic rats fed a high-fat diet, an increase
in islet triglyceride content precedes hyperglycemia (Lee et al.,
1994). There is also an inverse correlation between the amount
of fat in the human pancreas and glucose-induced insulin secre-
tion, with glucose tolerance and insulin secretion improving in
parallel with a reduction in pancreatic fat (Tushuizen et al.,
2007). This raises the interesting possibility that intrapancre-
atic/intraislet fat depositions provide a long-term local source
of FFA that adversely affects b cell function.
How Do Studies of Monogenic Diabetes Inform
Our Understanding of T2DM?
Recent years have seen considerable advances in our under-
standing of the genetic origin and associated phenotype of
several types of monogenic diabetes. The confounding effects
of obesity are less important in these disorders, suggesting
that it may be possible to glean information on the etiology of
T2DM by comparing it with monogenic diabetes.
Current evidence favors the idea that insufficient glucose-
stimulated insulin secretion is primarily responsible for T2DM.
As discussed above, estimates of b cell mass in T2DM vary
but do not appear sufficient to account for the disease. More-
over, the ability of GLP-1, or bariatric surgery, to restore
glucose-induced insulin secretion and plasma glucose to normal
levels in patients with T2DM argues that neither b cell mass nor
insulin content is severely reduced. This implicates defective
b cell function as the cause of T2DM.
Where does this defect occur? As T2DM is not associated
with impaired secretion from other endocrine organs, metabolic
and exocytotic pathways common to all endocrine cells cannot
be adversely affected; it must be some process unique to
the b cell. Given the key role of KATP channels and the ability of
sulphonylureas to enhance insulin secretion in T2DM, it is
tempting to attribute the impaired insulin secretion to slight
overactivity of KATP channels. However, any such overactivity
cannot be as great as in ND patients with KATP-channel muta-
tions because agents such as arginine and GLP-1, which work
only when KATP channels are largely closed, are still effective
secretagogs in T2DM but not in ND. These considerations
suggest that T2DM may be associated with mild impairment
of metabolism and/or the KATP channel itself, leading to a
small reduction in KATP-channel closure when blood glucose
increases. A key question is whether this is sufficient to explain
the diabetes.
Reduced activity of glucokinase cannot be solely responsible
for T2DM as the phenotype of the disease does not mimic that of
patients with either heterozygous or homozygous GCK muta-
tions. Impaired mitochondrial metabolism has been postulated
to contribute to T2DM (Maechler and Wollheim, 2001), and an
age-dependent decline in mitochondrial function might help
explain why T2DM develops later in life (in lean individuals).
However, if impaired metabolic regulation of KATP-channel
activity were the only problem in T2DM, then the phenotypewould resemble that of patients with ND or GCK mutations,
which it does not.
This suggests that additional processes, downstream of KATP-
channel closure, that regulate the amplifying response to
glucose or exocytosis itself also contribute to T2DM. Together
with a slight deterioration of metabolic function and insulin
content with age, these might lead to impaired glucose toler-
ance, thus setting in progress a vicious cycle in which slight
hyperglycemia produces downregulation of critical genes,
impairs the amplifying effects of glucose, and leads to a progres-
sive decline in b cell function (Weir and Bonner-Weir, 2004).
Obesity, via insulin resistance, would place an increased func-
tional demand on the b cell and accelerate b cell failure.
Therapies for T2DM
AsT2DMprogresses, bloodglucose levels rise andbcell function
progressively declines. Treatment options are complex, with
patients starting on oral antidiabetic agents, but most soon
proceeding to insulin injections;manyalso takedrugs that reduce
insulin resistance. Almost all of the current therapeutic interven-
tions lead to weight gain and an increased risk of hypoglycemia
and have little if any impact on disease progression.
Recent years have seen the introduction of incretin-based
therapies. GLP-1 has a half-life of 1 min in the plasma and is
rapidly degraded by the enzyme dipeptidyl peptidase 4
(DPP4), so it cannot be used itself (Deacon et al., 2008).
However, inhibitors of DPP4, or stable GLP-1 analogs, are very
effective at enhancing glucose-stimulated insulin secretion.
Their efficacy demonstrates that even in people with diabetes
of long duration, sufficient b cell capacity exists to maintain nor-
moglycemia, supporting the idea that impaired b cell function is
the prime cause of the disease. In rodents, GLP-1 also increases
islet cell functional mass (Xu et al., 1999), although it is uncertain
whether this applies to human islets (Parnaud et al., 2008).
Plasma GLP-1 levels are lower in T2DM, but the extent to which
a diminished incretin effect contributes to disease progression is
unknown (Holst, 2007). Most recently, agonists against novel G
protein-coupled receptors, including GPR119, GPR40,
GPR120, and GPR43 (Kebede et al., 2009), that have the poten-
tial to stimulate not only pancreatic b cells but also the cells in the
gut that release incretin hormones have emerged as possible
treatments for diabetes. In addition, anti-inflammatory agents,
such as interleukin-1-receptor antagonists, that improve glyce-
mic control and b cell function are entering trial programs (Man-
drup-Poulsen et al., 2010).
Diabetes is usually considered to be a chronic disease, asso-
ciatedwith a progressive reduction in b cell mass and irreversible
b cell failure that cannot be cured and requires lifelong therapy.
However, over the past 10 years, two independent sets of
studies have challenged this view. First, severe energy restriction
was able to reverse established T2DM within 1 week (Lim et al.,
2011). Second, patients who undergo bariatric surgery often
show remission of diabetes long before there is any substantial
weight loss (Karra et al., 2010).
The purpose of bariatric surgery is to enhance weight loss in
morbid obesity. Two different types of gastric bypass are
routinely employed: gastric banding and Roux-en-Y bypass
(RYGB) (Karra et al., 2010). Intriguingly, both methods result inCell 148, March 16, 2012 ª2012 Elsevier Inc. 1167
Figure 3. Diet Affects Diabetes Incidence
New cases of diabetes diagnosed in Norway during the years 1925–1955
(expressed as a percentage of the population). Diabetes incidence is higher in
individuals >60 years of age (i.e., with T2DM) than those <30 years of age (most
of whom will have T1DM). Although the incidence of T1DM remains
unchanged, T2DM decreases by 85% during the 1940–1945 German occu-
pation. This figure is modified from Westlund (1966).a rapid resolution (within days) of T2DM (Karra et al., 2010).
Meta-analysis indicated that diabetes resolves in 70% of
patients after RYGB and somewhat fewer patients after gastric
banding (Buchwald et al., 2009). The rapid improvement of
glucose tolerance cannot be accounted for by the weight loss,
which is much slower, but is associated with increased insulin
sensitivity and often (but not always) increased insulin secretion
(Falke´n et al., 2011; Isbell et al., 2010). The mechanisms involved
have not yet been elucidated, but proposed explanations include
increased release of the incretin hormone GLP-1, an altered
gut microbiotic environment, and caloric restriction. Bariatric
surgery is so effective that in 2011 it was approved by the Inter-
national Diabetes Federation as an appropriate therapy for
morbidly obese patients with T2DM.
Interestingly, the effects of bariatric surgery can be mimicked
by a very low-calorie diet (600 kcal/day) (Lim et al., 2011), which
normalizes plasma glucose levels within 4–7 days. In itself, this is
not so remarkable. During World War II, the number of people
with newly diagnosed T2DM in several European countries
crashed, only to rise after the end of food rationing (despite the
restricted diet, people were not starving) (Figure 3) (Westlund,
1966). In the most recent Balkan war, glycemic control signifi-
cantly improved in T2DM patients, as did obesity (Kulenovic
et al., 1996). However, there have been few studies of how
reduced caloric intake leads to diabetes remission. The signifi-
cance of the study by Lim and colleagues (Lim et al., 2011) is
that it illustrates just how fast diabetes resolves. This correlates
with a marked fall in hepatic glucose output and insulin resis-
tance, which normalizes glycemia. The underlying mechanism
is unclear. There is also a gradual restoration of glucose-induced
biphasic insulin secretion that mirrors a reduction in pancreatic
fat content. This suggests that a factor derived from intrapancre-
atic fat depots may exert a negative effect on b cell function. The
identity of this factor remains unknown, but local release of FFAs
is one of several possible candidates.1168 Cell 148, March 16, 2012 ª2012 Elsevier Inc.Conclusions
The last 10 years have seenmajor advances in both the scientific
understanding and the treatment of diabetes. PNDM has been
recognized as a monogenic disorder, separate from T1DM,
with which it was previously confused. The understanding of
themolecular basis of ND and the introduction of a novel therapy
(oral sulphonylureas) for patients with KATP channel or HNF1A
mutations constitute a real breakthrough. Importantly, tailoring
therapy to an individual’s genetic constitution in this way has
led to improved glycemic control and a far better quality of life.
There has also been unprecedented progress in identification
of genes that are highly significantly associated with T2DM. Like
any discovery, their identification precipitates a plethora of new
questions and heralds a daunting amount of new functional
work. But it also provides an opportunity for gaining important
new insights into b cell function. Although it was always appreci-
ated that T2DM is a polygenic disease, few would probably have
guessed how many genes are involved, or which ones they
would turn out to be. Indeed, the 40 genes identified already
are enough that each diabetic could have their own unique
combination of gene variants underlying their disease. At
present, known SNPs are of little or no value in predicting an indi-
vidual’s risk of T2DM, clinical translation has so far beenminimal,
and it remains to be seen whether they will be of therapeutic
value. Rather, their importance lies in the insights they provide
into the pathophysiology of disease and potential therapeutic
targets. Unraveling their roles will be challenging but rewarding.
The idea that multiple genes and multiple etiologies underlie
T2DM suggests that there will be an associated multiplicity of
phenotypes. One lesson from monogenic diabetes studies is
that different genotypes are associated with distinct pheno-
types, a finding of considerable significance for disease diag-
nosis, choice of therapy, and an understanding of disease
mechanism. This suggests that it will be important to phenotype
T2DMpatients more fully. A valuable approachmight be to focus
on lean T2DM patients, where the confounding effects of obesity
and insulin resistance are minimal.
Finally, we point out that although there is a strong genetic
predisposition to T2DM, shared by many of the population,
most people are not doomed to become diabetic. The massive
increase in diabetes incidence in recent years is not due to
genetic changes but is a consequence of the rise in obesity. It
is clear that weight control is highly beneficial in T2DM, and
recent studies show that it is even possible to reverse estab-
lished disease by bariatric surgery and caloric restriction (at least
in patients who have had diabetes for only a few years). The big
problem is that dietary compliance is very difficult to achieve and
is rarely perfect. Thus it may be appropriate to consider radical
measures such as taxing high-fat foods, as has recently been im-
plemented in Denmark. The examples of cigarette smoking and
alcohol intake suggest that such a tax might be an effective
deterrent to excess consumption.ACKNOWLEDGMENTS
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